| MeSH term | MeSH ID | Detail |
|---|---|---|
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
| Sacroiliitis | D058566 | 1 associated lipids |
| Plaque, Atherosclerotic | D058226 | 7 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Chlamydophila Infections | D023521 | 4 associated lipids |
| Epilepsy, Partial, Motor | D020938 | 1 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| alpha 1-Antitrypsin Deficiency | D019896 | 3 associated lipids |
| Tooth, Nonvital | D019553 | 2 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Carcinoma, Lewis Lung | D018827 | 22 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Romero-Gómez M et al. | Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. | 2003 | Aliment. Pharmacol. Ther. | pmid:14616169 |
| Kamada T et al. | The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12869086 |
| Lamouliatte H et al. | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535872 |
| Miehlke S et al. | Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535873 |
| Gisbert JP et al. | Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10540045 |
| Sasaki A et al. | Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. | 2003 | Aliment. Pharmacol. Ther. | pmid:12823156 |
| Yousfi MM et al. | One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8853767 |
| Gisbert JP and Calvet X | Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. | 2011 | Aliment. Pharmacol. Ther. | pmid:21745241 |
| Elizalde JI et al. | Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876713 |
| Hawkey CJ et al. | Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. | 2003 | Aliment. Pharmacol. Ther. | pmid:12694089 |
| Leiper K et al. | Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. | 2008 | Aliment. Pharmacol. Ther. | pmid:18315579 |
| Cammarota G et al. | High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. | 2004 | Aliment. Pharmacol. Ther. | pmid:15043520 |
| Ford AC et al. | Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. | 2007 | Aliment. Pharmacol. Ther. | pmid:17944741 |
| Pilotto A and Malfertheiner P | Review article: an approach to Helicobacter pylori infection in the elderly. | 2002 | Aliment. Pharmacol. Ther. | pmid:11929385 |
| Xiao SD et al. | A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. | 2001 | Aliment. Pharmacol. Ther. | pmid:11136281 |
| Wong WM et al. | Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16423001 |
| Zullo A et al. | Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. | 2007 | Aliment. Pharmacol. Ther. | pmid:17539982 |
| Savarino V et al. | The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10886045 |
| Wang WH et al. | High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. | 2000 | Aliment. Pharmacol. Ther. | pmid:10886046 |
| Chen PY et al. | Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074519 |